ANI Pharmaceuticals Inc (OQ:ANIP)
Business Focus: Pharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 210 Main Street West BAUDETTE MN 56623 |
| Tel: | 1-212-4522793 |
| Website: | https://www.anipharmaceuticals.com |
| IR: | See website |
| Key People | ||
| Nikhil Suresh Lalwani President, Chief Executive Officer, Director | Muthusamy Shanmugam Director, Head of Research and Development, Chief Operating Officer - Novitium Operations | Stephen P. Carey Chief Financial Officer, Senior Vice President |
| Krista Davis Chief Human Resource Officer, Senior Vice President | Meredith W. Cook Senior Vice President, General Counsel, Corporate Secretary | Chad Gassert Senior Vice President - Corporate Development and Strategy |
| Ori Gutwerg Senior Vice President - Generics | James G. Marken Senior Vice President - Operations | Christopher K. Mutz Senior Vice President, Head of Rare Diseases | Thomas Andrew Rowland Senior Vice President - Head of Established Brands |
| Business Overview |
| ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset, Purified Cortrophin Gel, as well as its generics business with enhanced research and development capabilities. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of approximately 118 products with a variety of indications and a robust portfolio of pipeline products. |
| Financial Overview |
| For the nine months ended 30 September 2024, ANI Pharmaceuticals Inc revenues increased 19% to $423.8M. Net loss applicable to common stockholders totaled $9.5M vs. income of $14.8M. Revenues reflect Rare Disease segment increase of 95% to $105.6M, United States segment increase of 15% to $285.2M, International segment increase from $0K to $1.2M. Net loss reflects Selling, General and administrative increase of 54% to $160M (expense). |
| Employees: | 642 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $1,745M as of Sep 30, 2024 |
| Annual revenue (TTM): | $555.46M as of Sep 30, 2024 |
| EBITDA (TTM): | $66.67M as of Sep 30, 2024 |
| Net annual income (TTM): | -$8.77M as of Sep 30, 2024 |
| Free cash flow (TTM): | $75.15M as of Sep 30, 2024 |
| Net Debt Last Fiscal Year: | $472.08M as of Sep 30, 2024 |
| Shares outstanding: | 21,028,639 as of Nov 1, 2024 |
| Index Membership: | S&P 600 Small Cap |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.